Background--Radiation therapy (RT) is a standard treatment for head and neck cancer; however, it is associated with inflammation, accelerated atherosclerosis, and cerebrovascular events (CVEs; stroke or transient ischemic attack). Human papillomavirus (HPV) is found in nearly half of head and neck cancers and is associated with inflammation and atherosclerosis. Whether HPV confers an increased risk of CVEs after RT is unknown.
S
urvival with head and neck cancer (HNCA) has significantly improved. 1 Radiation therapy (RT) to the neck is a standard primary treatment for HNCA 2 ; however, RT that involves the neck is associated with a 5-to 17-fold increased risk of cerebrovascular events (CVEs; stroke or transient ischemic attack [TIA] ). 3, 4 The mechanisms for this increase in CVEs after RT that involves the neck are not completely understood but likely are related to inflammation and accelerated atherosclerosis in the carotid artery. 4 The excess risk of CVEs after RT to the neck is only partially explained by traditional cardiovascular stroke risk factors 5 ; therefore, research is needed to understand whether additional factors can explain the increased risk of CVEs after RT in this vulnerable population. Significant epidemiological and scientific data suggest that human papillomavirus (HPV) may be a significant risk factor for CVEs after RT: HPV infection is common and has been estimated at up to 11% to 12% worldwide, and oncogenic HPV has been recognized as a primary risk factor for the development of HNCA. [5] [6] [7] Currently, well over one third of all HNCAs are linked to HPV, with oropharyngeal cancers testing positive in >70% of new cases alone. 8 Preliminary data suggest that HPV may promote atherosclerosis and may be a risk factor for CVEs after RT. Specifically, inhibition of macrophage p53 and Rb (retinoblastoma protein) are linked to the oncogenicity of HPV and to inflammation and accelerated atherosclerosis. [9] [10] [11] [12] Furthermore, data suggest that vaginal HPV status may be associated with an increased risk of cardiovascular events in women. 13 Consequently, because HPV is increasingly recognized as a risk factor for HNCAs and HPV is linked to atherosclerosis and inflammation in the general population, we hypothesized that positive HPV tumor status in HNCA compared with negative HPV tumor status may be associated with an increased risk of CVEs among patients treated with neck RT. Specifically, we postulated that a robust clinical oncogenic HPV infection, as reflected by the development of HPV-associated HNCA, is also likely associated with the disproportionately increased risk of CVEs after RT to the neck.
Methods Study Patients
Using an institutional database, we retrospectively identified all patients with HNCA who underwent neck RT and who also had neck-tumor-related HPV testing over an 11-year period, from January 2002 to December 2012. Two teams of independent investigators performed all data collection, including cardiovascular and cancer-specific variables, as well as event adjudication. Variables collected represented data available at the time of initiation of RT. We excluded patients who received neck RT before January 2002 because of inconsistent data availability. The study protocol was approved by our institutional human subjects research review committee, and the requirement for informed consent was waived.
HPV Identification
The decision to pursue testing was presumed related to the type of tumor and the data associating HPV with HNCA that evolved during the study period. high-risk probes were no longer commercially available, polymerase chain reaction amplification of purified DNA using the SPF (short polymerase chain reaction fragment) primer system, which amplified a 65-bp region of the conserved L1 viral capsid gene, became the primary method of testing for both low-and high-risk HPV (Inno-LiPA; Innogenetics). 15, 16 In addition, during the same period, reflex testing for the presence of p16 was incorporated for cases of squamous cell origin because p16 protein expression is generally considered a surrogate for HPV infection (Genpoint; Dako). 17 All tumor study results were verified by an experienced pathologist.
Outcomes
The primary outcome was the occurrence of a post-RT CVE. This was specifically defined as a composite of ischemic stroke and TIA. We chose this outcome based on data showing an increase in the combination of stroke and TIA after neck RT. 3, 4, 18 Death was also reported but was not the focus of this study. 19 CVEs were adjudicated by investigators (blinded to HPV status and all other variables) using recommended standardized definitions for stroke and TIA from recent published consensus American Heart Association and American Stroke Association definitions of stroke. 20 As such, ischemic stroke was defined as an episode of neurological dysfunction caused by focal cerebral, retinal, or spinal infarction. Available computed tomography and magnetic resonance neuroimaging reports were also reviewed for additional confirmation. TIA was defined as transient (<24 hours) stroke symptoms and the absence of objective cerebral, retinal, or spinal infarction, as seen with imaging or pathology.
Statistical Analysis
Continuous data are presented as meanAESD. Comparisons between groups (HPV-positive versus -negative patients) and baseline characteristics were performed with the use of an independent sample t test for continuous variables, the What Are the Clinical Implications?
• Determination of human papillomavirus tumor status may help guide clinicians in the assessment of stroke and transient ischemic attack risk following neck radiotherapy.
examine associations between the independent variables and the development of CVEs. Covariates included in the model were variables significant on univariate analysis as well as known predictors and confounders of CVEs. 3, 20 Hazard ratios (HRs) for the association of HPV status with events were estimated using Cox proportional hazards. Time of follow-up was calculated from the start of RT, and censoring criteria included death, first stroke or TIA, or last documented visit for those without events or death. For all analyses, a 2-tailed P value of <0.05 was considered significant. In addition, we performed competing risk analyses using death as the competing risk, given the expected difference in survival based on HPV tumor status, to further assess the impact of HPV status on cerebrovascular outcomes. From these analyses, an HR for CVE risk was obtained, adjusting for age, male sex, race, baseline lipids, blood pressure, history of diabetes mellitus, smoking, and use of antihypertensive medications. Those participants with HPV testing performed were more likely to be nonsmokers, to be male, to have oropharyngeal cancer, and to have received platinum-based or taxol chemotherapy. Inverse probability weighting was used to account for the nonrandomness of missing HPV genotype status. Statistical tests were performed using STATA version 14.1 (StataCorp).
Results
The final cohort included 326 patients treated with neck RT who were tested for HPV ( Figure 1 ). The mean age of the entire cohort at the time of RT was 59AE12 years (range: 20-83 years), and 75% were male. The characteristics of the study population by HPV status are summarized in Table 1 . Overall, 191 (59%) were tumor HPV positive. In addition, 89% of all included participants were treated with chemotherapy plus RT, 53% were comanaged with surgery, and 3% were treated with RT alone. Patients with HPV infection were more likely to be male and to have oropharyngeal cancer and less likely to have laryngeal carcinoma as their cancer type. There was no difference in the prevalence of baseline coronary or cerebrovascular disease or of traditional cardiovascular risk factors among groups with and without HPV.
HPV Status and Cerebrovascular Outcomes
From the final cohort, there were 23 CVEs over median followup of 3.4 years (range: 1-14 years) yielding a total event rate of 7.0% and an annual event of 1.8% per year. There were 18 CVEs (15 strokes and 3 TIAs) in HPV-positive patients compared with 5 events in the HPV-negative patients (3 strokes and 2 TIAs). The annual rate for CVEs was 2.6% per year in HPV-positive persons compared with 0.9% per year in the HPV-negative persons (unadjusted P=0.01). Median time to event among HPV-positive participants was 3.4 years compared with 4.2 years in those who were HPV negative (P=0.876). In a Kaplan-Meier analysis stratified by tumor HPV status, HPV positivity was associated with events that began %2 years after RT and persisted throughout the duration of follow-up ( Figure 2) . A representative set of images from an HPV-positive participant that had a TIA after RT is shown in Figure 3 . We observed no significant difference in baseline covariates between those with and without events other than HPV status (19 
Discussion
This study provides the first clinical evidence that tumor HPV infection in HNCA patients is associated with a higher risk of ischemic stroke and TIA following RT. Overall, HPV-positive tumor status conferred a >4-fold increased risk of CVEs following RT that involved the neck. This result remained, even after accounting for more traditional CVE risk factors. Separation in event curves was apparent within 3.5 years of post-RT follow-up. These observations are of clinical importance because of the increasing prevalence of HPV-associated HNCA and survival of patients as well as the limited number of available tools for ischemic stroke and TIA risk stratification among patients treated with RT. To our knowledge, this report is the first linking HPV status with the risk of stroke and TIA following RT for HNCA. The predictors of CVEs among RT-treated participants are incompletely understood. Data from the general population suggest that traditional established risk factors for CVEs, such as hypertension, diabetes mellitus, dyslipidemia, active smoking, and atrial fibrillation, account for nearly 90% of all stroke events. 21 In contrast, in an analysis of >50 000 RTtreated HNCA patients, traditional risk factors (hypertension and diabetes mellitus) were observed in only 30% of stroke events. 22 Consequently, there are likely other risk factors that may at least partially explain the >500% increased risk of stroke events faced by HNCA patients treated with RT. 3, 4 In this study, we found that HPV status was predictive of stroke and TIA following RT, even after adjustment for traditional risk factors and RT dose. This is important, particularly because HPV is prevalent among those who go on to develop HNCAs and is a potentially modifiable risk factor. 23 Although there are no available prior studies investigating the relationship between HPV status and CVEs in RT-treated HNCA patients, multiple investigators have reported parallel findings in other populations that are supportive of the current results. 12, 24, 25 Data from the National Health Insurance
Research Database of Taiwan showed a >50% increase in the risk of ischemic stroke for women treated with RT involving the neck for cervical cancer. 24 In that study, the investigators postulated that the elevated stroke risk was primarily related to systemic injury caused by RT. In addition, analysis from the US National Health and Nutrition Examination Survey data set revealed a >2-fold increased risk of cardiovascular disease, including stroke, among young women with vaginal HPV infection without known cancer. 13 Furthermore, recent pathologic data from Lawson et al demonstrated a >50% prevalence of oncogenic HPV infection in the atheromatous coronary plaques of donors deceased from acute myocardial infarction. 25 Taken together, these studies provide support for the underlying association of HPV with the accelerated development of atherosclerosis leading stroke and TIA following RT, as noted in this study. Several potential mechanisms may explain these findings. Consistent animal data suggest that the HPV-inhibited macrophage p53 and Rb tumor suppressor genes play important roles in the development of atherosclerosis. 12, 26 Specifically, p53 inhibition has been shown to accelerate atherosclerotic growth through extracellular proliferation, reduction of apoptotic cellular activity, and direct increases in atherosclerotic lesion area. 12, 26, 27 The inhibition of Rb has also been linked to increases in atherosclerotic lesion size as well as smooth muscle cell proliferation. 27 Furthermore, inflammation has been postulated as a common pathway of viral-mediated injury and atherosclerosis. 25, 28 Caspases, which are protein enzymes that are vital to the process of vascular inflammation and cellular apoptosis, have been linked with the development of atherosclerosis, and recent reports have suggested that HPV E6 oncoproteins may promote nuclear localization of active caspase 8, leading to increased inflammation and probable atherosclerosis. 29, 30 Furthermore, it may be reasonable to postulate that the downstream vascular effects of RT-induced endothelial damage and medial fibrosis may be enhanced by oncogenic HPVinduced cellular proliferation, allowing for stimulation of the proliferation of damaged vascular cells and leading to accelerated atherosclerosis 4, 31 ; however, further studies are needed. Our study has limitations. Data on tumor cell type were only inconsistently reported and thus was not included in this analysis. HPV testing was performed at the discretion of the treating medical oncologist; therefore, only a subset of the entire cohort had HPV status available. Nevertheless, when inverse probability weighting was used to account for these missing HPV genotypic data, all study findings remained significant. As with other studies examining the prevalence of HPV-associated HNCAs, oropharyngeal carcinoma accounted for a majority of the patients included and thus represents a large proportion of the cohort studied. 5, 7, 10 Given the retrospective nature of the study, available follow-up within the cohort was nonuniform, which may have limited the ability to capture additional events. In addition, although observed events were adjudicated by the study team, the specific etiology of observed stroke events was not consistently available across all participants, given reliance on the documentation of non-study members. Relative quantities of alcohol consumption were not consistently available across participants. Although the number of persons included in this analysis was small, the annual CVE rate was significant, consistent with previous neck RT reports. 3, 4 In conclusion, HNCA patients treated with neck RT face a significant downstream risk of CVEs. The presence of HPVinfection appears to be strongly associated with that risk. Determination of HPV tumor status may help guide clinicians in the assessment of stroke and TIA risk following neck RT. Future studies of HNCA patients treated with RT are needed to evaluate potential stroke prevention strategies based on HPV status.
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